Microfluidic synthesis of fibronectin-coated polydopamine nanocomplexes for self-supplementing tumor microenvironment regulation and MR imaging-guided chemo-chemodynamic-immune therapy

Development of nanomedicines to overcome the hindrances of tumor microenvironment (TME) for tumor theranostics with alleviated side effects remains challenging. We report here a microfluidic synthesis of artesunate (ART)-loaded polydopamine (PDA)/iron (Fe) nanocomplexes (NCs) coated with fibronectin (FN). The created multifunctional Fe-PDA@ART/FN NCs (FDRF NCs) with a mean size of 161.0 ​nm exhibit desired colloidal stability, monodispersity, r₁ relaxivity (4.96 ​mM^-1s^-1), and biocompatibility. The co-delivery of the Fe²⁺ and ART enables enhanced chemodynamic therapy (CDT) through improved intracellular reactive oxygen species generation via a cycling reaction between Fe³⁺ and Fe²⁺ caused by the Fe³⁺-mediated glutathione oxidation and Fe²⁺-mediated ART reduction/Fenton reaction for self-supplementing TME regulation. Likewise, the combination of ART-mediated chemotherapy and the Fe²⁺/ART-regulated enhanced CDT enables noticeable immunogenic cell death, which can be collaborated with antibody-mediated immune checkpoint blockade to exert immunotherapy having significant antitumor immunity. The combined therapy improves the efficacy of primary tumor therapy and tumor metastasis inhibition by virtue of FN-mediated specific targeting of FDRF NCs to tumors with highly expressed α_vβ₃ integrin and can be guided through the Fe(III)-rendered magnetic resonance (MR) imaging. The developed FDRF NCs may be regarded as an advanced nanomedicine formulation for chemo-chemodynamic-immune therapy of different tumor types under MR imaging guidance.

Vapochromic effect in switchable molecular-based spin crossover compounds

Coordination complexes based on transition metal ions displaying [Ar]3d⁴-3d⁷ electronic configurations can undergo the likely most spectacular switchable phenomena found in molecular coordination chemistry, the well-known Spin Crossover (SCO). SCO phenomena is a detectable, reproducible and reversible switch that occurs between the high spin (HS) and low spin (LS) electronic states of the transition metal actuated by different stimuli (i.e. light, temperature, pressure, the presence of an analyte). Moreover, the occurrence of SCO phenomena causes different outputs, one of them being a colour change. Altogether, an analyte in gas form could be detected by naked eye once it has triggered the corresponding HS ↔ LS transition. This vapochromic effect could be used to detect volatile molecules using a low-cost technology, including harmful chemical substances, gases and/or volatile organic compounds (VOCs) that are present in our environment, in our home or at our workplace. The present review condenses all reported iron coordination compounds where the colour change induced by a given molecule in its gas form is coupled to a HS ↔ LS spin transition. Special emphasis has been made on describing the nature of the post-synthetic modification (PSM) taking place in the material upon the analyte uptake. In this case, three types of PSM can be distinguished: based on supramolecular contacts and/or leading to a coordinative or covalent bond. In the latter, a colour change not only indicates the switch of the spin state in the material but also the formation of a new compound with different properties. It is important to indicate that some of the SCO coordination compounds discussed in the current report have been part of other spin crossover reviews, that have gathered thermally induced SCO compounds and the influence of guest molecules on the SCO behaviour. However, in the majority of examples in these reviews, the change of colour upon the uptake of analytes is not associated with a spin transition at room temperature. In addition, the observed colour variations have been mainly discussed in terms of host-guest interactions, when they can also be induced by a PSM taking place in different sites of the molecule, like the Fe(II) coordination sphere or by chemically altering its inorganic and/or organic linkers. Therefore, we present here for the first time an exhaustive compilation of all systems in which the interaction between the coordination compounds and the vapour analytes leads to a colour change due to a spin transition in the metal centre at room temperature.

Surface engineered mesoporous silica carriers for the controlled delivery of anticancer drug 5-fluorouracil: Computational approach for the drug-carrier interactions using density functional theory

Introduction: Drug delivery systems are the topmost priority to increase drug safety and efficacy. In this study, hybrid porous silicates SBA-15 and its derivatives SBA@N and SBA@3N were synthesized and loaded with an anticancer drug, 5-fluorouracil. The drug release was studied in a simulated physiological environment. Method: These materials were characterized for their textural and physio-chemical properties by scanning electron microscopy (SEM), nuclear magnetic resonance (NMR), Fourier transform infrared spectroscopy (FTIR), small-angle X-ray diffraction (SAX), and nitrogen adsorption/desorption techniques. The surface electrostatics of the materials was measured by zeta potential. Results: The drug loading efficiency of the prepared hybrid materials was about 10%. In vitro drug release profiles were obtained in simulated fluids. Slow drug release kinetics was observed for SBA@3N, which released 7.5% of the entrapped drug in simulated intestinal fluid (SIF, pH 7.2) and 33% in simulated body fluid (SBF, pH 7.2) for 72 h. The material SBA@N presented an initial burst release of 13% in simulated intestinal fluid and 32.6% in simulated gastric fluid (SGF, pH 1.2), while about 70% of the drug was released within the next 72 h. Density functional theory (DFT) calculations have also supported the slow drug release from the SBA@3N material. The release mechanism of the drug from the prepared carriers was studied by first-order, second-order, Korsmeyer-Peppas, Hixson-Crowell, and Higuchi kinetic models. The drug release from these carriers follows Fickian diffusion and zero-order kinetics in SGF and SBF, whereas first-order, non-Fickian diffusion, and case-II transport were observed in SIF. Discussion: Based on these findings, the proposed synthesized hybrid materials may be suggested as a potential drug delivery system for anti-cancer drugs such as 5-fluorouracil.

Promising nanomaterials in the fight against malaria

For more than one hundred years, several treatments against malaria have been proposed but they have systematically failed, mainly due to the occurrence of drug resistance in part resulting from the exposure of the parasite to low drug doses. Several factors are behind this problem, including (i) the formidable barrier imposed by the Plasmodium life cycle with intracellular localization of parasites in hepatocytes and red blood cells, (ii) the adverse fluidic conditions encountered in the blood circulation that affect the interaction of molecular components with target cells, and (iii) the unfavorable physicochemical characteristics of most antimalarial drugs, which have an amphiphilic character and can be widely distributed into body tissues after administration and rapidly metabolized in the liver. To surpass these drawbacks, rather than focusing all efforts on discovering new drugs whose efficacy is quickly decreased by the parasite's evolution of resistance, the development of effective drug delivery carriers is a promising strategy. Nanomaterials have been investigated for their capacity to effectively deliver antimalarial drugs at local doses sufficiently high to kill the parasites and avoid drug resistance evolution, while maintaining a low overall dose to prevent undesirable toxic side effects. In recent years, several nanostructured systems such as liposomes, polymeric nanoparticles or dendrimers have been shown to be capable of improving the efficacy of antimalarial therapies. In this respect, nanomaterials are a promising drug delivery vehicle and can be used in therapeutic strategies designed to fight the parasite both in humans and in the mosquito vector of the disease. The chemical analyses of these nanomaterials are essential for the proposal and development of effective anti-malaria therapies. This review is intended to analyze the application of nanomaterials to improve the drug efficacy on different stages of the malaria parasites in both the human and mosquito hosts.

Encapsulation and controlled release of an antimalarial drug using surface functionalized mesoporous silica nanocarriers

Herein, we report the encapsulation and release of antimalarial drug quinine (QN) using three nanocarriers, including MCM-41 (1), and its 3-aminopropyl silane (aMCM-41 (2)) and 3-phenylpropyl silane (pMCM-41 (3)) surface functionalized derivatives. The pH and thermal optimization effects on QN adsorption and release from 1, 2 and 3 were investigated.

Mesoporous silica nanocarriers encapsulated antimalarials with high therapeutic performance

The use of nanocarriers in drug delivery is a breakeven research and has received a clarion call in biomedicine globally. Herein, two newly nano-biomaterials: MCM-41 encapsulated quinine (MCM-41 ⊃ QN) (1) and 3-phenylpropyl silane functionalized MCM-41 loaded QN (pMCM-41 ⊃ QN) (2) were synthesized and well characterized. 1 and 2 along with our two already reported nano-antimalarial drugs (MCM-41 ⊃ ATS) (3) and 3-aminopropyl silane functionalized MCM-41 contained ATS (aMCM-41 ⊃ ATS) (4) were screened in vitro for their activity against P. falciparium W2 strain, cytotoxicity against BGM cells and in vivo for their activity against Plasmodium bergheiNK65. 1 has the highest antimalarial activity in vivo against P. berghei NK65, (ED50: < 0.0625 mg/kg body weight) and higher mean survival time compared to the other nano biomaterials or unencapsulated drugs at doses higher than 0.0625 mg/kg body weight. This encapsulation strategy of MCM-41 ⊃ QN (1) stands very useful and effective in delivering the drug to the target cells compared to other delivery systems and therefore, this encapsulated drug may be considered for rational drug design.